Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

NCT00656812 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma of Mucosa-Associated Lymphoid Tissue

Interventions

DRUG: Rituximab
DRUG: 2-CdA

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborators

[object Object]
[object Object]